美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Mace Security International, Inc.

0.0157

0.0000

成交量：- -

成交额：- -

市值：104.42万

市盈率：-0.40

高：0.0157

开：0.0157

低：0.0157

收：0.0157

52周最高：0.0157

52周最低：0.0157

股本：6,659.61万

流通股本：6,121.55万

量比：0.11

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.0391

每股收益(LYR):-0.0309

净资产收益率：-106.94%

总资产收益率：-19.75%

市净率：0.51

市盈率(LYR):-0.51

数据加载中...

总览公司新闻资讯公告

减肥版司美格鲁肽在中国获批新适应症，系中国首个！减重药为啥要管这件事？

未来已来，看口服司美如何重塑糖尿病的治疗价值

告别针头！口服司美格鲁肽片实现16.6%体重减轻

不止减重，司美格鲁肽亮出心血管获益王牌

上半年创新药对外授权近660亿美元；司美格鲁肽最新数据出炉

21世纪经济报道

在GLP-1（胰高血糖素样肽-1）减肥药的竞争中诺和诺德的司美格鲁肽终于凭借心血管方面的获益扳回一局。9月1日记者从诺和

礼来Muvalaplin片启动III期临床适应症为降低伴Lp(a)水平升高患者MACE发生风险

复星医药、康方生物最新业绩公布；勃林格殷格翰新药获批 | 动脉“医”周报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/MACE/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MACE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","market":"US","secType":"STK","nameCN":"Mace Security International, Inc.","latestPrice":0.01568,"timestamp":1771621200000,"preClose":0.01568,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":61215490,"shares":66596075,"eps":-0.039075,"marketStatus":"休市中","change":0,"latestTime":"02-20 16:00:00 EST 延时","open":0.01568,"high":0.01568,"low":0.01568,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.039075,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.01568,"volumeRatio":0.10668023659160104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","floatShares":61215490,"roa":"-19.75%","roe":"-106.94%","lyrEps":-0.030906,"volumeRatio":0.10668023659160104,"shares":66596075,"dividePrice":0,"high":0.01568,"amplitude":0,"preClose":0.01568,"low":0.01568,"week52Low":0.01568,"pbRate":"0.51","psRate":"0.18","week52High":0.01568,"institutionHeld":0.0001,"latestPrice":0.01568,"eps":-0.039075,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.039075,"open":0.01568,"prevYearClose":0.01568,"prevWeekClose":0.0157,"prevMonthClose":0.0157,"prevQuarterClose":0.0157,"fiveDayClose":0.0157,"twentyDayClose":0.0157,"sixtyDayClose":0.0157},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MACE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-09","symbol":"MACE","reason":null,"defaultRemindTime":1733754600000,"announcedDate":"2024-12-06","type":"delisting","dateTimestamp":1733720400000},{"market":"US","date":"2024-09-30","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1727668800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-02","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1712030400000,"reportTimeType":"","actualEps":null},{"date":"2023-11-14","symbol":"MACE","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1699995600000,"name":null,"time":"盘后","dateTimestamp":1699938000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MACE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MACE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MACE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593043353","title":"减肥版司美格鲁肽在中国获批新适应症，系中国首个！减重药为啥要管这件事？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593043353","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593043353?lang=zh_cn&edition=fundamental","pubTime":"2025-12-22 21:56","pubTimestamp":1766411806,"startTime":"0","endTime":"0","summary":"2025年已近尾声，减重药赛道的竞争没有丝毫放松。就在今天（12月22日），司美格鲁肽注射液（商品名：诺和盈）的心血管适应症上市申请获得中国国家药品监督管理局（NMPA）批准，适用于降低已确诊为心血管疾病、且BMI≥27成人患者的主要心血管不良事件（心血管死亡、非致死性心肌梗死、非致死性卒中）的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598584460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MACE","BK4157","BK4183"],"gpt_icon":0},{"id":"2590518307","title":"未来已来，看口服司美如何重塑糖尿病的治疗价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518307?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 16:37","pubTimestamp":1765355850,"startTime":"0","endTime":"0","summary":"第二代的长效及速效胰岛素联合应用，已成为糖尿病晚期管理的核心，但可能面临低血糖和体重增加等问题。“口服化”必然成为糖尿病治疗发展的新方向。在实现治疗便利性、且保证疗效的同时，口服司美格鲁肽在心血管保护和降低肾病风险方面的表现也引发业内关注。目前，2型糖尿病患者在降糖、降低心血管疾病及肾病风险方面的综合代谢治疗获益已经成为内分泌专业医生的治疗关注重点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MACE","BK4183","BK4157"],"gpt_icon":0},{"id":"2570909606","title":"告别针头！口服司美格鲁肽片实现16.6%体重减轻","url":"https://stock-news.laohu8.com/highlight/detail?id=2570909606","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570909606?lang=zh_cn&edition=fundamental","pubTime":"2025-09-25 17:10","pubTimestamp":1758791432,"startTime":"0","endTime":"0","summary":"结果显示：在严格遵循治疗的患者中，口服司美格鲁肽片25 mg组体重降幅达16.6%，显著高于安慰剂组的2.7%；34.4%的受试者减重超过20%，而安慰剂组这一比例仅为2.9%。即使考虑部分患者用药依从性不足的情况，口服组仍实现13.6%的体重降幅，近30%的患者减重超过20%。其中，司美格鲁肽注射液表现尤为突出，单季度销售额高达8.16亿元，占据市场主导地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925182127a4433b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925182127a4433b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4157","LU1093756168.USD","BK4183","BK4585","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","BK4007","BK4532","BK4588","MACE","NVO"],"gpt_icon":1},{"id":"2568459038","title":"不止减重，司美格鲁肽亮出心血管获益王牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2568459038","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568459038?lang=zh_cn&edition=fundamental","pubTime":"2025-09-17 10:30","pubTimestamp":1758076249,"startTime":"0","endTime":"0","summary":"诺和诺德更是明确指出：诺和盈所展现的心脏保护获益是司美格鲁肽分子独有。事实上，司美格鲁肽在心血管保护方面的显著获益在机制研究阶段已有迹可循。该研究首次证实了诺和盈是全球首个在伴有确诊心血管疾病但无糖尿病的超重或肥胖成人中，显示出心血管结局获益的减重药物4。在全球范围内，每年约有2,100万人死于心血管疾病6。约有三分之二与肥胖相关的死亡与心血管疾病相关7,8。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091711560497979a96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091711560497979a96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1035773651.USD","LU0985320562.USD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU1057294990.SGD","LU0203347892.USD","LU1430594728.SGD","SG9999001176.SGD","LU1929549753.HKD","LU1069347547.HKD","LU2023250504.SGD","IE00BN8TJ469.HKD","BK4550","BK4599","LU2468319806.SGD","LU1116320901.HKD","BK4585","LU1571399168.USD","IE00B1BXHZ80.USD","BK4588","LU2361044949.HKD","LU2023250843.SGD","SG9999014575.USD","LU0208291251.USD","LU0122379950.USD","LU1061106388.HKD","LU1934455863.HKD","RCT","IE00BBT3K403.USD","LU1291159041.SGD","LU2089984988.USD","IE00B2B36J28.USD","IE0009355771.USD","LU1162221912.USD","LU1934455277.USD","SGXZ57979304.SGD","NVO","IE00BLSP4239.USD","LU1917777945.USD","LU1066051225.USD","LU0289739699.SGD","LU2324357040.USD","LU0965509010.AUD","MACE","LU1066053197.SGD","SG9999002232.USD","IE00BSNM7G36.USD","MRK","IE000M9KFDE8.USD","LU1585245621.USD"],"gpt_icon":1},{"id":"2564823056","title":"上半年创新药对外授权近660亿美元；司美格鲁肽最新数据出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2564823056","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564823056?lang=zh_cn&edition=fundamental","pubTime":"2025-09-02 07:59","pubTimestamp":1756771151,"startTime":"0","endTime":"0","summary":"政策动向国家药监局副局长徐景和：上半年创新药对外授权金额近660亿美元9月1日，国家药监局副局长徐景和在2025年“全国药品安全宣传周”启动仪式上表示，即将收官的“十四五”，是持续释放政策红利的五年，医药产业创新发展更加有为、更加有力。2025年上半年创新药对外授权总金额已接近660亿美元，全球市场对中国创新药的认可度正在不断提升。地方上，去年共抽检药品216164批次，不合格率0.39%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902080149a4ae467f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902080149a4ae467f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4157","O","BK4599","LLY","BK4588","LU1093756168.USD","IE00BZ1G4Q59.USD","AD","LU1093756325.SGD","BK4132","BK4007","MACE","NVO","BK4183","BK4585","IE00BKVL7J92.USD","BK4532","Y"],"gpt_icon":1},{"id":"2564807899","title":"在GLP-1（胰高血糖素样肽-1）减肥药的竞争中诺和诺德的司美格鲁肽终于凭借心血管方面的获益扳回一局。9月1日记者从诺和","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807899","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564807899?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 14:33","pubTimestamp":1756708413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4144","NVO","IE00BZ1G4Q59.USD","MACE","BK4532","BK4588","BK4590","LU1093756168.USD","GLP","BK4007","BK4585","LU1093756325.SGD","LU0154236417.USD","BK4183","BK4157","IE00BKVL7J92.USD","BK4599"],"gpt_icon":0},{"id":"2564898466","title":"礼来Muvalaplin片启动III期临床 适应症为降低伴Lp(a)水平升高患者MACE发生风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2564898466","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564898466?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 12:31","pubTimestamp":1756701060,"startTime":"0","endTime":"0","summary":"本次试验主要目的为在伴有Lp水平升高且发生过ASCVD事件或发生首次ASCVD事件风险升高的成人参与者中评价Muvalaplin对主要不良心血管事件影响。Muvalaplin片为化学药物，适应症为在伴Lp水平升高且已确诊CVD或发生首次CVE风险升高的患者中，降低MACE的发生风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU2237443622.USD","SG9999018865.SGD","SGXZ81514606.USD","SG9999018857.SGD","IE00B2B36J28.USD","LU0097036916.USD","LU0114720955.EUR","LU0672654240.SGD","LU2461242641.AUD","LU1720051017.SGD","III","LU0238689110.USD","MACE","LU2552382215.SGD","SGXZ57979304.SGD","LU2237438978.USD","LU2750360997.AUD","LU0079474960.USD","LU2471134952.CNY","SGXZ51526630.SGD","LU0256863902.USD","LU2491050071.SGD","SGXZ99366536.SGD","LU0385154629.USD","LU0432979614.USD","LLY","LU0094547139.USD","LU0823434583.USD","LU0122379950.USD","LU2468319806.SGD","BK4599","LU0203201768.USD","LU2746668461.USD","LU0198837287.USD","LU1280957306.USD","LU2746668974.SGD","LU2602419157.SGD","BK4588","LU0354030511.USD","LU1366192091.USD","GB00BDT5M118.USD","LU0889565916.HKD","Y","LU0109391861.USD","LU2237443549.SGD","LU0466842654.USD","LU1548497426.USD","LU1974910355.USD","LU1267930730.SGD","LU0471298777.SGD"],"gpt_icon":1},{"id":"2563216290","title":"复星医药、康方生物最新业绩公布；勃林格殷格翰新药获批 | 动脉“医”周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2563216290","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563216290?lang=zh_cn&edition=fundamental","pubTime":"2025-08-29 21:27","pubTimestamp":1756474020,"startTime":"0","endTime":"0","summary":"Daphne 作者：实习生陈川、郑奥、贺朵1国内企业动态新药进展三生制药个体化rhTPO方案疗效优于艾曲泊帕8月21日，中国医学科学院血液病医院张磊教授团队在《eClinicalMedicine》发表了“TE-ITP研究”成果。详细结果将于未来医学会议公布。财报数据复星医药发布2025半年报8月26日，复星医药发布2025年半年度业绩报告。和铂医药公布2025中期业绩8月27日，和铂医药公布其2025中期业绩。此次更新取消了此前要求患者必须确诊心血管疾病的条件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508292142309769fb28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508292142309769fb28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0882574139.USD","LU1366192091.USD","IE0002141913.USD","IE0009355771.USD","01801","BK4007","LU1069344957.HKD","LU2357305700.SGD","LU2471134879.HKD","LU0094547139.USD","ITP","LU1868837300.USD","02142","LU0097036916.USD","LU0203202063.USD","LU1548497426.USD","LU2456880835.USD","LU2471134952.CNY","09926","LU2361045086.USD","LU2552382132.HKD","LU0417517546.SGD","LLY","LU0122379950.USD","LU1917777945.USD","LU1023059063.AUD","LU2237443895.HKD","LU0823434583.USD","Y","LU2112291526.USD","HR","SGXZ99366536.SGD","LU2602419157.SGD","BK4157","LU0256863811.USD","01177","LU2491050154.USD","MACE","LU1989771016.USD","LU2552382215.SGD","LU1267930730.SGD","SGXZ51526630.SGD","LU0198837287.USD","LU2360106947.USD","LU1551013425.SGD","09688","IE00BK4W5L77.USD","LU0323591593.USD","LU1061106388.HKD","LU1720051108.HKD","LU2264538146.SGD","LU0466842654.USD","LU2491049909.HKD","LU0109391861.USD","LU1974910355.USD","LU2746668461.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}